1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside

Protein kinases are key regulators of cell function that constitute one of the largest and most functionally diverse gene families with approximately 518 kinases encoded by the human genome. They direct the activity, localization and overall function of many proteins, and serve to orchestrate the activity of almost all cellular pathways. Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival.
To date, the industry is developing cancer drugs targeting close to 30% of all known human protein kinases and 29 kinase inhibitors have so far received approval as cancer treatments. As kinase signaling cascades involve an intricate array of interconnected circuits we need to develop more sophisticated modeling of how they are reprogrammed in response to oncogenic events and in the presence of inhibitors. This information will be vital to more rational application and combinations of different inhibitors dependent on the molecular profile of the tumor.

BioSeeker's "Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside" is a novel tool for instant, interactive pathway modeling on close to 725 protein kinase inhibitor drugs across more than 125 different kinase targets or 95 different tumor types. It serves the purpose of giving you a breakdown analysis of how successful the industry is today in targeting various signaling pathways with kinase inhibitors in oncology or to research new treatment options with the same. You dynamically control the pathway modeling with up to 24 different parameter settings, including both traditional drug development data such as status, indication etc. as well as system biology information such as mutation profile, protein expression, pathway etc. Moreover, each parameter supports multi-select options and can be used as either an inclusion or exclusion parameter for your modeling. Furthermore, your modeling and analysis results are presented to you in a report supported by graphical visualization aids such as charts, diagrams and tables. As an additional value this tool also gives you instant access to extensive drug developmental profiles of all 724 protein kinase inhibitor drugs included.

All together this tool gives you superiority in access and control over drug development options when it comes to protein kinase inhibitors in oncology, not commercially available anywhere else.

The Pathway Analyzer is delivered to you electronically as a desktop application which runs locally. One year of free data and feature updates is included in your purchase.

System Requirements
- Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
- Browser Application (Internet Explorer, Firefox, Chrome, Safari)
- Internet access (to access related internet resources)

Table Of Contents

Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...

Global Cancer Monoclonal Antibodies Market 2017-2021

Global Cancer Monoclonal Antibodies Market 2017-2021

  • $ 3500
  • Industry report
  • December 2016
  • by Infiniti Research Limited

About Cancer Monoclonal Antibodies The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.